logo
Menu

We provide briefings on technologies to different public stakeholders, from those delivering care and research funders stimulating innovation, to policy makers and advisory bodies. Most, if not all of these briefings, will be publicly available on this website via the search window.

Innovation Observatory > Reports > Drugs > Lusutrombopag (Mulpleta) for severe thrombocytopenia in patients with chronic liver disease undergoing an elective invasive procedure

< Back

Lusutrombopag (Mulpleta) for severe thrombocytopenia in patients with chronic liver disease undergoing an elective invasive procedure

Drugs

Gastrointestinal, Pancreatic and Liver Disease

December 2016


Lusutrombopag is a new drug to treat one of the symptoms of long-term liver disease, where low numbers of blood cells called platelets lead to poor blood clotting. This can lead to uncontrolled bleeding during surgery or other procedures, which can lead to delay or cancellation of treatment. The drug increases the number of platelets to make important procedures safe to perform. Lusutrombopag is taken as a tablet once a day for up to seven days. Lusutrombopag may offer a new treatment for low platelet levels in patients with liver disease and may be an alternative to the use of donor platelet infusions.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts